• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转铁蛋白受体表达与非霍奇金淋巴瘤组织学分类及预后的相关性

Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma.

作者信息

Habeshaw J A, Lister T A, Stansfeld A G, Greaves M F

出版信息

Lancet. 1983 Mar 5;1(8323):498-501. doi: 10.1016/s0140-6736(83)92191-8.

DOI:10.1016/s0140-6736(83)92191-8
PMID:6131211
Abstract

The proportion of lymphocytes from patients with non-Hodgkin lymphoma (NHL) expressing transferrin receptors in biopsy material from lymph-nodes assayed by binding of the monoclonal antibody OKT9 correlated significantly with the histological class of the tumour. High-grade lymphomas contained 22.5% (range 3-57%) OKT9-positive lymphocytes, and low-grade lymphomas contained 2.5% (range less than 1-22). Since histological class of lymphoma is an important factor in survival, it was expected and confirmed that OKT9 levels were related to survival in these patients. Transferrin receptor is expressed by growing cells. The correlates observed in this series of NHL suggests a relation between transferrin receptor and either the growth fraction, or factors affecting the growth fraction, of the tumour.

摘要

通过单克隆抗体OKT9结合法检测非霍奇金淋巴瘤(NHL)患者淋巴结活检材料中表达转铁蛋白受体的淋巴细胞比例,与肿瘤的组织学类型显著相关。高度恶性淋巴瘤含有22.5%(范围3%-57%)的OKT9阳性淋巴细胞,低度恶性淋巴瘤含有2.5%(范围小于1%-22%)。由于淋巴瘤的组织学类型是生存的一个重要因素,因此可以预期并得到证实,OKT9水平与这些患者的生存相关。转铁蛋白受体由生长中的细胞表达。在这一系列NHL中观察到的相关性表明转铁蛋白受体与肿瘤的生长分数或影响生长分数的因素之间存在关联。

相似文献

1
Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma.转铁蛋白受体表达与非霍奇金淋巴瘤组织学分类及预后的相关性
Lancet. 1983 Mar 5;1(8323):498-501. doi: 10.1016/s0140-6736(83)92191-8.
2
The cellular content of non Hodgkin lymphomas: a comprehensive analysis using monoclonal antibodies and other surface marker techniques.非霍奇金淋巴瘤的细胞成分:使用单克隆抗体及其他表面标志物技术的综合分析
Br J Cancer. 1983 Mar;47(3):327-51. doi: 10.1038/bjc.1983.52.
3
An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site.在人类淋巴瘤肿瘤进展过程中优先暴露的转铁蛋白受体上的一个表位靠近配体结合位点。
Blood. 1991 Feb 15;77(4):826-32.
4
Transferrin receptor expression by non-Hodgkin's lymphomas. Correlation with morphologic grade and survival.
Cancer. 1988 May 1;61(9):1844-51. doi: 10.1002/1097-0142(19880501)61:9<1844::aid-cncr2820610921>3.0.co;2-z.
5
Expression of three cell proliferation-associated antigens, DNA polymerase alpha, Ki-67 antigen and transferrin receptor in nodal and cutaneous T-cell lymphomas.
Int J Hematol. 1991 Oct;54(5):385-93.
6
Transferrin receptor expression in reactive and neoplastic lesions of lymphnodes.转铁蛋白受体在淋巴结反应性和肿瘤性病变中的表达
Indian J Pathol Microbiol. 2007 Apr;50(2):433-6.
7
HNK-1+ cells in non-Hodgkin's lymphoma: lack of relation with transferrin receptor expression on malignant cells.非霍奇金淋巴瘤中的HNK-1+细胞:与恶性细胞上转铁蛋白受体表达缺乏相关性
Br J Cancer. 1985 Feb;51(2):171-7. doi: 10.1038/bjc.1985.26.
8
Immunohistological study of transferrin receptor expression in non-Hodgkin's lymphoma.非霍奇金淋巴瘤中转铁蛋白受体表达的免疫组织学研究。
Br J Haematol. 1984 Nov;58(3):501-8. doi: 10.1111/j.1365-2141.1984.tb03997.x.
9
Growth fraction of tumour cells and infiltration density with natural killer-like (HNK1+) cells in non-Hodgkin lymphomas.非霍奇金淋巴瘤中肿瘤细胞的生长分数及自然杀伤样(HNK1+)细胞的浸润密度
Br J Haematol. 1986 Feb;62(2):293-300. doi: 10.1111/j.1365-2141.1986.tb02932.x.
10
Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas.转铁蛋白受体与B淋巴细胞母细胞抗原——它们与B细胞淋巴瘤中DNA合成、组织学及生存情况的关系
Int J Cancer. 1984 Feb 15;33(2):173-7. doi: 10.1002/ijc.2910330204.

引用本文的文献

1
Revised model for cell cycle regulation by iron: differential roles between transferrin and ferritin.铁调控细胞周期的修订模型:转铁蛋白与铁蛋白的不同作用
Redox Biol. 2025 Jun 11;85:103727. doi: 10.1016/j.redox.2025.103727.
2
Transferrin Receptor Promotes Endometrial Cancer Proliferation by Activating the Iron-Dependent PI3K/AKT/mTOR Signaling Pathway.转铁蛋白受体通过激活铁依赖性PI3K/AKT/mTOR信号通路促进子宫内膜癌增殖。
Cancer Sci. 2025 May;116(5):1352-1365. doi: 10.1111/cas.70015. Epub 2025 Mar 1.
3
Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology.
针对白血病治疗的铁死亡靶向治疗:基于纳米技术从机制和白血病中的作用探索新策略。
Eur J Med Res. 2024 Apr 9;29(1):224. doi: 10.1186/s40001-024-01822-7.
4
Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway.转铁蛋白受体 1 通过激活 mTOR 信号通路促进肝癌的进展和转移。
Hepatol Int. 2024 Apr;18(2):636-650. doi: 10.1007/s12072-023-10607-9. Epub 2023 Nov 20.
5
Expression Is Promoted by Tank Binding Kinase 1 () in Pancreatic Cancer Cells to Increase Iron and Reduce the Expression of E-Cadherin.在胰腺癌细胞中, Tank结合激酶1( )促进其表达,以增加铁含量并降低E-钙黏蛋白的表达。
Antioxidants (Basel). 2022 Jul 27;11(8):1460. doi: 10.3390/antiox11081460.
6
Discovery of a Transferrin Receptor 1-Binding Aptamer and Its Application in Cancer Cell Depletion for Adoptive T-Cell Therapy Manufacturing.发现转铁蛋白受体 1 结合适体及其在用于过继性 T 细胞治疗制造的癌细胞耗竭中的应用。
J Am Chem Soc. 2022 Aug 3;144(30):13851-13864. doi: 10.1021/jacs.2c05349. Epub 2022 Jul 24.
7
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.CX-2029,一种抗 CD71 前药药物偶联物的非临床疗效和安全性。
Mol Cancer Ther. 2022 Aug 2;21(8):1326-1336. doi: 10.1158/1535-7163.MCT-21-0193.
8
Peptide-Conjugated Nano Delivery Systems for Therapy and Diagnosis of Cancer.用于癌症治疗与诊断的肽缀合纳米递送系统
Pharmaceutics. 2021 Sep 9;13(9):1433. doi: 10.3390/pharmaceutics13091433.
9
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents.靶向转铁蛋白受体1(TfR1)的抗体作为直接抗癌剂
Front Immunol. 2021 Mar 17;12:607692. doi: 10.3389/fimmu.2021.607692. eCollection 2021.
10
Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy.人类癌症中的铁调节异常:代谢改变、诊断、预后、监测的生物标志物及治疗原理
Cancers (Basel). 2020 Nov 26;12(12):3524. doi: 10.3390/cancers12123524.